---
schema_version: "secwatch.filing_event.v1"
accession: "0001860782-24-000060"
form_type: "8-K"
ticker: null
cik: "0001860782"
company_name: "2seventy bio, Inc."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T08:15:24.628694+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# 2seventy bio announces Q1 2024 Abecma U.S. revenue of $52M

## Summary
- Abecma generated approximately $52M in U.S. Q1 2024 revenue, unaudited.
- Company and BMS share equally in all profits and losses for Abecma in the U.S.
- Full Q1 2024 results to be announced on or before May 15, 2024.

## SEC filing metadata
- accession: 0001860782-24-000060
- form_type: 8-K
- cik: 0001860782
- company_name: 2seventy bio, Inc.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000060/0001860782-24-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000060/tvst-20240425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001860782-24-000060
- JSON: https://secwatch.observer/filing/0001860782-24-000060.json
- Plain text: https://secwatch.observer/filing/0001860782-24-000060.txt

## Key facts
- Earnings Releases
  2seventy bio, Inc. reported the first quarter of 2024 results: revenue $52 million.
  - Period: the first quarter of 2024
  - Revenue: $52 million
  - Result: preliminary results
  source text: On April 25, 2024, 2seventy bio, Inc. (the “Company”) announced that Abecma (idecabtagene vicleucel, or ide-cel) generated approximately $52 million in U.S. revenue during the first quarter of 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000060/0001860782-24-000060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.